69 studies found for:    Pertuzumab
Show Display Options
Rank Status Study
1 Recruiting Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma
Condition: Esophageal Carcinoma
Intervention: Drug: Pertuzumab, trastuzumab
2 Active, not recruiting Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Conditions: Neuroendocrine Carcinoma;   Neuroendocrine
Interventions: Drug: Bevacizumab;   Drug: Pertuzumab;   Drug: Sandostatin LAR® Depot
3 Recruiting Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Condition: Breast Neoplasms
Interventions: Drug: Trastuzumab;   Drug: pertuzumab;   Drug: lapatinib
4 Recruiting A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine [Kadcyla];   Drug: trastuzumab [Herceptin];   Drug: pertuzumab [Perjeta];   Drug: taxane;   Drug: anthracycline-based chemotherapy
5 Active, not recruiting Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Conditions: Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage III Colon Cancer;   Stage III Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Biological: pertuzumab;   Biological: cetuximab;   Drug: irinotecan hydrochloride;   Other: immunohistochemistry staining method;   Other: fluorescence in situ hybridization;   Other: gene expression analysis;   Other: mutation analysis;   Other: polymerase chain reaction;   Other: laboratory biomarker analysis
6 Recruiting Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: pertuzumab;   Biological: trastuzumab;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
7 Recruiting A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine [Kadcyla];   Drug: pertuzumab [Perjeta];   Drug: trastuzumab [Herceptin];   Drug: docetaxel;   Drug: carboplatin
8 Recruiting Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Condition: Her2-Positive Breast Cancer
Interventions: Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: 5-fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
9 Active, not recruiting A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Condition: Breast Cancer
Interventions: Drug: pertuzumab;   Drug: pertuzumab-placebo;   Drug: trastuzumab [Herceptin];   Drug: docetaxel;   Drug: paclitaxel;   Drug: trastuzumab emtansine
10 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
Condition: Metastatic Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg;   Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg;   Drug: Pertuzumab 420 mg
11 Recruiting Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: pertuzumab in combination with trastuzumab and paclitaxel
12 Recruiting Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1
Condition: Elderly Metastatic Breast Cancer Population
Interventions: Drug: Pertuzumab + trastuzumab;   Drug: Pertuzumab + trastuzumab + metronomic chemotherapy
13 Recruiting A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: pertuzumab [Perjeta];   Drug: placebo;   Drug: trastuzumab [Herceptin];   Drug: cisplatin;   Drug: capecitabine;   Drug: 5-fluorouracil
14 Active, not recruiting A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: pertuzumab;   Drug: trastuzumab;   Drug: cisplatin;   Drug: capecitabine
15 Recruiting Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
Condition: HER-2 Positive Breast Cancer
Intervention: Drug: Pertuzumab, Trastuzumab and Eribulin
16 Recruiting Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: docetaxel;   Drug: carboplatin;   Biological: trastuzumab;   Biological: pertuzumab;   Drug: goserelin acetate;   Procedure: therapeutic conventional surgery;   Radiation: whole breast irradiation;   Other: laboratory biomarker analysis;   Drug: aromatase inhibition therapy;   Other: quality-of-life assessment
17 Recruiting Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
Condition: HER2-positive Metastatic Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Paclitaxel;   Drug: Vinorelbine;   Drug: T-DM1
18 Active, not recruiting A Study of Perjeta (Pertuzumab) in Combination With Herceptin in Patients With Metastatic Breast Cancer.
Condition: Breast Cancer
Intervention: Drug: pertuzumab [Perjeta]
19 Completed A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study
Condition: Solid Cancers
Intervention: Drug: pertuzumab
20 Completed A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: rhuMAb 2C4 (pertuzumab)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years